Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerard Lozanski

Showing results (71-80 of 134) with videos related to

Pageof 14
Sort By:
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 9, 2016
Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host DiseaseSumithira Vasu, Susan Geyer, Anissa Bingman, et al.
Blood Advances|January 4, 2018
BRAF<sup>V600E</sup> accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemiaYo-Ting Tsai, Aparna Lakshmanan, Amy Lehman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 14, 2016
Erratum to "Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease" [Biol Blood Marrow Transplant 22(2016):658-668]Sumithira Vasu, Susan Geyer, Anissa Bingman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2012
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502Eyal C Attar, Jeffrey L Johnson, Philip C Amrein, et al.
Cytometry. Part B, Clinical Cytometry|May 6, 2017
A QA Program for MRD Testing Demonstrates That Systematic Education Can Reduce Discordance Among Experienced InterpretersMichael Keeney, Brent L Wood, Benjamin D Hedley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 11, 2018
Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and DexamethasoneJames P Dugan, Bradley M Haverkos, Lynda Villagomez, et al.
Leukemia & Lymphoma|September 19, 2017
Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemiaLeslie A Andritsos, Nicole R Grieselhuber, Mirela Anghelina, et al.
JCI Insight|June 20, 2020
LC-FACSeq is a method for detecting rare clones in leukemiaEileen Y Hu, James S Blachly, Caner Saygin, et al.
Blood|April 2, 2020
Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutationsFabienne Lucas, Karylin Larkin, C Thomas Gregory, et al.
The AAPS Journal|May 4, 2011
Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cellsSneha V Gupta, Ellen J Sass, Melanie E Davis, et al.
Pageof 14

Showing results (71-80 of 134) with videos related to

Sort By:
Pageof 14
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 9, 2016
Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host DiseaseSumithira Vasu, Susan Geyer, Anissa Bingman, et al.
Blood Advances|January 4, 2018
BRAF<sup>V600E</sup> accelerates disease progression and enhances immune suppression in a mouse model of B-cell leukemiaYo-Ting Tsai, Aparna Lakshmanan, Amy Lehman, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 14, 2016
Erratum to "Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease" [Biol Blood Marrow Transplant 22(2016):658-668]Sumithira Vasu, Susan Geyer, Anissa Bingman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2012
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502Eyal C Attar, Jeffrey L Johnson, Philip C Amrein, et al.
Cytometry. Part B, Clinical Cytometry|May 6, 2017
A QA Program for MRD Testing Demonstrates That Systematic Education Can Reduce Discordance Among Experienced InterpretersMichael Keeney, Brent L Wood, Benjamin D Hedley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 11, 2018
Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and DexamethasoneJames P Dugan, Bradley M Haverkos, Lynda Villagomez, et al.
Leukemia & Lymphoma|September 19, 2017
Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemiaLeslie A Andritsos, Nicole R Grieselhuber, Mirela Anghelina, et al.
JCI Insight|June 20, 2020
LC-FACSeq is a method for detecting rare clones in leukemiaEileen Y Hu, James S Blachly, Caner Saygin, et al.
Blood|April 2, 2020
Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutationsFabienne Lucas, Karylin Larkin, C Thomas Gregory, et al.
The AAPS Journal|May 4, 2011
Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cellsSneha V Gupta, Ellen J Sass, Melanie E Davis, et al.
Pageof 14